Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026
Milestone Pharmaceuticals (Nasdaq: MIST) will report its fourth quarter and full-year 2025 results and provide a business update on Friday, March 20, 2026 before the market opens.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Milestone Pharmaceuticals (Nasdaq: MIST) will report its fourth quarter and full-year 2025 results and provide a business update on Friday, March 20, 2026 before the market opens. A conference call and webcast for investors is scheduled at 8:30am ET.
Access details include domestic and international dial‑in numbers, a conference ID, a Call me™ option active 15 minutes before start, and a replay available on the company’s Investors and Media website.
Details
News Market Reaction – MIST
On Mar 12, the day this news came out, MIST closed 2.34% above the previous close. That session’s volume was 1.7x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Mar 12 session.
Key Figures
- Earnings date
- March 20, 2026
- Fourth quarter and full-year 2025 results release before market open
- Conference time
- 8:30am ET
- Investor conference call and webcast start time on March 20, 2026
- US dial-in
- 1-877-407-0792
- Domestic participant dial-in number for earnings call
- International dial-in
- 1-201-689-8263
- International participant dial-in number for earnings call
- Conference ID
- 13759195
- Conference code required to join the earnings call
- Call me activation
- 15 minutes prior
- Call me link becomes active 15 minutes before call start
Historical Context
-
TD Cowen healthcare conference webcast and investor presentation details.
-
Appointment of new General Counsel tied to CARDAMYST commercial launch.
-
Stock option inducement grants to new employees under listing rule 5635(c)(4).
-
U.S. commercial availability of CARDAMYST nasal spray for PSVT.
-
EMA acceptance of MAA for etripamil nasal spray (TACHYMIST) in PSVT.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call and Webcast Scheduled for Friday, March 20 at 8:30am ET
MONTREAL and CHARLOTTE, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that it will report fourth quarter and full-year 2025 results and provide a business update on Friday, March 20, 2026, before the market opens. The announcement will be followed by a conference call and webcast for investors at 8:30am ET.
| Conference Details: | |
| Conference Dial-in: | 1-877-407-0792 |
| International Dial-in: | 1-201-689-8263 |
| Conference ID: | 13759195 |
| Webcast link: | click here |
Call me™: Participants can use Guest dial-in numbers above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. The Call me™ link will be made active 15 minutes prior to scheduled start time.
A replay of the audio webcast of the call will be available under the “Investors and Media” section of Milestone's corporate website, www.milestonepharma.com.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST™ (etripamil) nasal spray, a novel calcium channel blocker, which is FDA approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in development for the control of symptomatic episodic attacks associated with AFib-RVR.
Contact:
Investor Relations
Kevin Gardner, kgardner@lifesciadvisors.com
Media Relations
Rebecca Novak, rnovak@milestonepharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.